A U.S. Food and Drug Administration (FDA) review to date has not identified adverse...

A U.S. Food and Drug Administration (FDA) review to date has not identified adverse health effects from gadolinium retained in the brain after the...

Mallinckrodt Acthar Gel phase IV clinical study with relapsing multiple sclerosis

STAINES-UPON-THAMES, United Kingdom Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4...

Novartis multiple sclerosis drug Gilenya shows siginificant effect against pediatric MS in phase III...

Novartis MS Drug Gilenya shows siginificant effect in phase III trial: Against Pediatric MSNovartis’ multiple sclerosis (MS) drug Gilenya (fingolimod) has demonstrated significant effect...

Celgene announces data on its phase III relapsing MS Ozanimod experimental treatment

Study met the primary endpoint of annualized relapse rate (ARR) and key secondary MRI endpoints of T2 and GdE lesions, compared to interferon (IFN)...

Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS

SOURCE Novartis- Breakthrough Therapy designation can expedite the development and review of therapies for serious conditions- In a pivotal Phase III study, oral fingolimod...

Advanced Practice Providers Treat Significantly More of their Multiple Sclerosis Patients with Monoclonal Antibody...

Market access restrictions for high efficacy Multiple Sclerosis therapies may be hindering their ability to optimally treat their clinically complex, relapsing patients, according to...

Using Statin’s in multiple sclerosis treatment

Scientists are hopeful a major drug trial will establish that statins can be used to treat multiple sclerosis.The low-cost drugs are typically prescribed to...

New Inroads Against Multiple Sclerosis

JAMA recently published their interviews with two MS Specaists focusing on the medical progress against multiple sclerosis (MS) in 2017 with the approval by the...

Biogen’s 8% Increase to Some MS Medications Could Provide a Boost in 2018

Market Watch reports Biogen Inc.'s BIIB, +4.90% recent price increases on multiple sclerosis drugs "could provide lift into '18," according to RBC Capital Markets...

Social Media

683FollowersFollow